GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Botanix Pharmaceuticals BOT.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.01

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2026

Revenue

A$34.5m

FY2017FY2026

Net income

−A$69.8m

FY2017FY2026

Free cash flow

−A$64.6m

FY2017FY2026

Shareholders' equity

A$63.5m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueA$34.5mA$5.8mA$601,820A$914,973A$2.8mA$6.9mA$7.6mA$4.7mA$1.8mA$46,500
Research and development—A$143,950A$1.8mA$5.7mA$10.3mA$6.6mA$13.7mA$16.6mA$11.0mA$3.7m
Operating income−A$68.0m−A$82.9m−A$15.7m−A$12.7m−A$15.9m−A$10.3m−A$29.5m−A$21.8m−A$22.1m−A$8.4m
Net income−A$69.8m−A$86.4m−A$13.9m−A$9.2m−A$13.2m−A$3.3m−A$16.7m−A$17.0m−A$11.0m−A$4.8m
Diluted earnings per share-0.03-0.04-0.01-0.01-0.01-0.00-0.02-0.02-0.01-0.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsA$106.0mA$129.1mA$112.5mA$24.8mA$14.0mA$22.0mA$25.3mA$5.2mA$17.7mA$5.9m
Cash and short-term investmentsA$36.6mA$65.0mA$79.3mA$10.3mA$7.3mA$21.6mA$24.6mA$4.7mA$17.3mA$5.7m
Total liabilitiesA$42.5mA$47.8mA$3.7mA$1.9mA$5.9mA$1.2mA$1.7mA$4.6mA$1.4mA$470,600
DebtA$14.7mA$32.5m——A$122,414A$259,318A$420,628A$420,624——
Shareholders' equityA$63.5mA$81.3mA$108.7mA$23.0mA$8.2mA$20.8mA$23.6mA$615,215A$16.3mA$5.4m
Shares outstanding2,386m1,964m1,817m1,439m1,022m973m973m909m760m544m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−A$64.6m−A$78.6m−A$8.1m−A$12.1m−A$11.2m−A$3.0m−A$17.4m−A$13.1m−A$9.9m−A$4.6m
Capital spending−A$3−A$286,430−A$18.0m−A$7.1m−A$2.9m−A$8,281−A$90,051−A$13,287−A$13,287−A$13,287
Free cash flow−A$64.6m−A$78.9m−A$26.1m−A$19.1m−A$14.1m−A$3.0m−A$17.4m−A$13.2m−A$9.9m−A$4.7m
Dividends paid———−A$1.3m−A$20.3m—−A$34.1m——−A$6.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023
RevenueA$18.0mA$16.5mA$5.4mA$377,597A$1.7mA$377,930A$526,976−A$142,531
Operating income−A$35.7m−A$33.6m−A$49.8m−A$32.0m−A$8.8m−A$5.5m−A$4.5m−A$2.3m
Net income−A$36.6m−A$33.2m−A$55.5m−A$30.9m−A$8.4m−A$5.5m−A$4.6m−A$2.3m
Diluted earnings per share-0.02-0.02-0.03-0.02-0.00-0.00-0.00-0.00
Cash from operations−A$31.0m−A$32.0m−A$48.0m−A$30.0m−A$4.0m−A$3.0m−A$6.0m−A$3.0m
Capital spending—————−A$14.0m−A$1.0m—
Free cash flow—————−A$17.0m−A$7.0m—
Total assetsA$106.0mA$98.6mA$129.1mA$99.4mA$112.5mA$47.7mA$24.8mA$24.8m
Cash and short-term investmentsA$36.6mA$31.6mA$65.0mA$48.4mA$79.3mA$18.3mA$10.3mA$10.3m
DebtA$25.3mA$30.0mA$32.5mA$866,352————
Shareholders' equityA$63.5mA$54.0mA$81.3mA$92.5mA$108.7mA$45.4mA$23.0mA$16.6m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue235.4%38.0%—
Operating income74.8%46.0%72.5%
Net income96.8%83.7%44.9%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-374.6%-429.1%-399.6%—
Net margin-387.5%-428.5%-380.3%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-0.4-1.8-15.6-8.2-1.1-4.5-2.0-0.5-0.3-0.4
Price to sales0.826.9360.482.05.42.24.41.71.742.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 3 Oct 1996.

FY1997FY1996FY1995FY1994
Paid in the year95.849194.011139.71681.959
  • 3333-to-1000 reverse split · 16 Jun 2016
  • 50-to-1 reverse split · 24 Jan 2014
  • 4-to-1 reverse split · 23 Aug 2004
  • 3-to-1 reverse split · 31 Jul 2001

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.